Neurogene Inc.
NGNEHealthcare|Biotechnology|US
$25.31
-0.34 (-1.33%)
DCF Value
$4.36
Tangible Book / Share
$9.63
Cash / Share
$9.99
About
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Stock Price
-5.1%(1Y)
1M
-4.5%
3M
-29.1%
6M
-17.8%
YTD
+22.9%
1Y
-10.6%
3Y
+86.7%
5Y
-82.1%
Pipeline Summary
6 total trials2
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
Completed: 2Terminated: 2Active: 2
Active Trials (2)
Gene Therapy Study for Children With CLN5 Batten Disease
NCT05228145Neuronal Ceroid Lipofuscinosis CLN5
Phase 1Phase 2Active
Enrollment: 6 participants
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
NCT05898620Rett Syndrome
Phase 3Active
Enrollment: 33 participants
Key Facts
Market Cap$400.0M
Employees131 (+22% YoY)
CEORachel L. McMinn
IPO DateMar 7, 2014
Beta2.09
52-Week Range$15.93 – $43.66
Avg Volume283,655
ExchangeNASDAQ
Websiteneurogene.com
Ownership
Float79.3%
Shares Outstanding15.8M
Recent Insider Trades
McMinn RachelOPTION EX.
Sep 22, 2026756 shares @ $25.32
McMinn RachelOPTION EX.
Sep 22, 2026756 shares @ $25.32
Cvijic Christine MikailSELL
Jul 6, 2026600 shares @ $36.02
Cvijic Christine MikailSELL
Jul 7, 20264,200 shares @ $36.13
Cvijic Christine MikailSELL
Jul 1, 2026739 shares @ $34.06
Peers
Recent News
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026 · businesswire.com
Neurogene to Participate in Upcoming Investor Conferences
Nov 3, 2026 · businesswire.com
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Oct 27, 2026 · gurufocus.com
Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome
Oct 27, 2026 · businesswire.com
Intellia Therapeutics (NASDAQ:NTLA) and Neurogene (NASDAQ:NGNE) Critical Survey
Oct 21, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:24 AM